Choosing omalizumab in severe allergic asthma: evidence and practices

Speciality: Pulmonary Medicine

Description:

A warm welcome to all the medical professionals in this interesting session on Choosing omalizumab in severe allergic asthma: evidence and practices
Omalizumab, an anti-IgE monoclonal antibody, has become a key treatment for patients with severe allergic asthma who remain uncontrolled despite standard therapies. By targeting IgE, a critical player in allergic responses, omalizumab helps reduce exacerbations, improve lung function, and enhance quality of life. Clinical evidence shows that it is particularly effective in patients with elevated serum IgE levels and frequent asthma attacks.
When choosing omalizumab, physicians consider factors like the patient’s IgE levels, asthma severity, and response to previous treatments. Guidelines support its use in patients with allergic asthma not controlled by inhaled corticosteroids and long-acting beta-agonists. Regular monitoring and patient education are essential, as the treatment is typically administered subcutaneously every 2 to 4 weeks, providing a personalized approach for managing severe asthma.
Therefore, get an overall knowledge of choosing omalizumab in severe allergic asthma: evidence and practices. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars